Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Renaissance International IPO ETF (NY: IPOS )

12.65 -0.37 (-2.84%)
Official Closing Price Updated: 4:10 PM EST, Dec 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Renaissance International IPO ETF

Weight-Loss Drug Gold Rush Gets Larger As New Player Fractyl Health Files For $100M IPO
Fractyl Health, developing procedural and gene therapies for type 2 diabetes and obesity, filed an S-1 filing with the SEC on Thursday to raise up to $100 million in an initial public offering. 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
European Private Equity CVC Capital Partners Defies Market Pessimism, Weighs Amsterdam IPO Next Week
CVC Capital Partners, one of Europe's leading private equity groups with €161 billion under management, is set to make an audacious move by announcing its intention to go public in Amsterdam. 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Instacart and Arm's Stock Decline Sparks Concerns Over Tech Sector IPOs
Investors in recently listed tech companies Arm Holdings Plc (NASDAQ:  
Via Benzinga
Radiopharmaceuticals Startup RayzeBio Seeks Public Debut After Raising $400M From Investors
RayzeBio Inc, a San Diego company focused on radiopharmaceutical therapies for cancer, filed on Thursday to raise up to $1 
Via Benzinga
Healthcare Software Firm Waystar Goes IPO Way With Potential $8B Valuation
Waystar Inc, a provider of financial management software for hospitals and medical practices, is reportedly making strides toward an initial public offering (IPO) that could value the company up to $8... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Second Time Charm: Sagimet Biosciences Seeks Public Debut With $75M IPO
On Friday, Sagimet Biosciences, a clinical-stage biopharmaceutical company, filed with the SEC to raise up to $75 million in an initial public off 
Via Benzinga
7 ETFs to Buy on Sale After Falling 30% in 2021
Some of the worst-performing funds of 2021 could be the best ETFs to buy for 2022. Here are seven that ought to rebound in the year ahead. 7 ETFs to Buy on Sale After Falling 30% or More in 2021 
Via InvestorPlace
2021 Likely to be a Record Year for IPOs: ETFs to Win
There have been 480 SPAC IPOs this year, with healthcare taking about 38% total volume, followed by technology (31% weight). Companies are also joining the IPO stream to go public in a stock market at... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
With IPOs Red Hot, What's Next for ETFs?
Capital markets are very hot this year. Money raised by US IPOs in 2021, including SPACs, is already the highest on record for any full year, per WSJ. 
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.